# FELIQS CORPORATION

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/feliqs

- Headquarters: Kurume, Japan
- Website: www.feliqs.com
- Total disclosed funding: $8.6M
- Latest round: Series A (Jul 1, 2025)
- Investors on record: 5

## About

Based in Japan, FELIQS CORPORATION focuses on developing innovative pharmaceutical products that target ferroptosis and oxidative lipids to treat pediatric diseases and age-related conditions.FELIQS CORPORATION, founded in 2019 in Kurume, Japan, develops pharmaceutical products with a focus on pediatric diseases. The company has raised a total of JPY 1,250.00 mn through its Series A funding round, with key investors including Beyond Next Ventures and Mitsubishi UFJ Capital. The founder's history is currently not detailed.FELIQS Inc. specializes in the development of pharmaceutical products targeting ferroptosis and oxidative lipids, particularly focusing on pediatric diseases and age-related conditions. Their flagship product, FLQ-101, is aimed at preventing retinopathy of prematurity, affecting premature infants, and they have developed a proprietary drug screening platform utilizing research from Kyushu University Graduate School of Pharmaceutical Sciences. Their products are marketed in Japan and the United States, catering to healthcare providers, hospitals, and research institutions involved in pediatric care and ophthalmology.FELIQS Inc. generates revenue through the development and commercialization of its pharmaceutical products, especially FLQ-101 and FLQ-105, which address retinopathy of prematurity and age-related macular degeneration, respectively. The company forms direct partnerships with healthcare entities and research institutions for B2B transactions, while revenue is realized through collaborations with pharmaceutical companies and potential licensing agreements that may include milestone payments and royalties on product sales, tailored according to negotiations and market conditions.FELIQS CORPORATION plans to utilize recent funding to accelerate the development of new products and expand its market presence. The company aims to enhance its product portfolio with upcoming launches focused on pediatric and age-related diseases and will target entry into additional global markets by 2025. The recent funding from investors such as Keio Innovation Initiative and Mitsubishi UFJ Capital is expected to support these initiatives.

## Funding rounds

- Series A, Jul 1, 2025, $8.6M — Mitsubishi UFJ Capital, Japan Science and Technology Agency, Beyond Next Ventures, Keio Innovation Initiative, FFG Venture Business Partners

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- Japan Science and Technology Agency — Series A
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series A
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series A
- FFG Venture Business Partners (https://capitalatlas.ai/funds/ffg-venture-business-partners) — Series A